IDYA
Price
$21.37
Change
-$0.92 (-4.13%)
Updated
Jun 27 closing price
Capitalization
1.87B
45 days until earnings call
VRTX
Price
$441.30
Change
-$2.10 (-0.47%)
Updated
Jun 27 closing price
Capitalization
113.32B
33 days until earnings call
Interact to see
Advertisement

IDYA vs VRTX

Header iconIDYA vs VRTX Comparison
Open Charts IDYA vs VRTXBanner chart's image
IDEAYA Biosciences
Price$21.37
Change-$0.92 (-4.13%)
Volume$3.2M
Capitalization1.87B
Vertex Pharmaceuticals
Price$441.30
Change-$2.10 (-0.47%)
Volume$3.62M
Capitalization113.32B
IDYA vs VRTX Comparison Chart in %
Loading...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IDYA vs. VRTX commentary
Jun 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDYA is a Hold and VRTX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 28, 2025
Stock price -- (IDYA: $21.39 vs. VRTX: $441.30)
Brand notoriety: IDYA and VRTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IDYA: 169% vs. VRTX: 176%
Market capitalization -- IDYA: $1.87B vs. VRTX: $113.32B
IDYA [@Biotechnology] is valued at $1.87B. VRTX’s [@Biotechnology] market capitalization is $113.32B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IDYA’s FA Score shows that 0 FA rating(s) are green whileVRTX’s FA Score has 2 green FA rating(s).

  • IDYA’s FA Score: 0 green, 5 red.
  • VRTX’s FA Score: 2 green, 3 red.
According to our system of comparison, VRTX is a better buy in the long-term than IDYA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IDYA’s TA Score shows that 4 TA indicator(s) are bullish while VRTX’s TA Score has 4 bullish TA indicator(s).

  • IDYA’s TA Score: 4 bullish, 5 bearish.
  • VRTX’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, VRTX is a better buy in the short-term than IDYA.

Price Growth

IDYA (@Biotechnology) experienced а -1.29% price change this week, while VRTX (@Biotechnology) price change was +0.10% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.22%. For the same industry, the average monthly price growth was +31.37%, and the average quarterly price growth was +12.88%.

Reported Earning Dates

IDYA is expected to report earnings on Aug 12, 2025.

VRTX is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+4.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VRTX($113B) has a higher market cap than IDYA($1.87B). VRTX YTD gains are higher at: 9.585 vs. IDYA (-16.770). VRTX has higher annual earnings (EBITDA): -74.9M vs. IDYA (-356.46M). VRTX has more cash in the bank: 6.2B vs. IDYA (693M). IDYA has less debt than VRTX: IDYA (26M) vs VRTX (1.65B). VRTX has higher revenues than IDYA: VRTX (11.1B) vs IDYA (7M).
IDYAVRTXIDYA / VRTX
Capitalization1.87B113B2%
EBITDA-356.46M-74.9M476%
Gain YTD-16.7709.585-175%
P/E RatioN/A32.76-
Revenue7M11.1B0%
Total Cash693M6.2B11%
Total Debt26M1.65B2%
FUNDAMENTALS RATINGS
IDYA vs VRTX: Fundamental Ratings
IDYA
VRTX
OUTLOOK RATING
1..100
6858
VALUATION
overvalued / fair valued / undervalued
1..100
62
Fair valued
77
Overvalued
PROFIT vs RISK RATING
1..100
6933
SMR RATING
1..100
9491
PRICE GROWTH RATING
1..100
4859
P/E GROWTH RATING
1..100
10032
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IDYA's Valuation (62) in the null industry is in the same range as VRTX (77) in the Biotechnology industry. This means that IDYA’s stock grew similarly to VRTX’s over the last 12 months.

VRTX's Profit vs Risk Rating (33) in the Biotechnology industry is somewhat better than the same rating for IDYA (69) in the null industry. This means that VRTX’s stock grew somewhat faster than IDYA’s over the last 12 months.

VRTX's SMR Rating (91) in the Biotechnology industry is in the same range as IDYA (94) in the null industry. This means that VRTX’s stock grew similarly to IDYA’s over the last 12 months.

IDYA's Price Growth Rating (48) in the null industry is in the same range as VRTX (59) in the Biotechnology industry. This means that IDYA’s stock grew similarly to VRTX’s over the last 12 months.

VRTX's P/E Growth Rating (32) in the Biotechnology industry is significantly better than the same rating for IDYA (100) in the null industry. This means that VRTX’s stock grew significantly faster than IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IDYAVRTX
RSI
ODDS (%)
Bearish Trend 1 day ago
71%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
64%
Momentum
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
42%
MACD
ODDS (%)
Bearish Trend 1 day ago
71%
Bullish Trend 1 day ago
64%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
80%
Bullish Trend 1 day ago
57%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
43%
Advances
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 5 days ago
59%
Declines
ODDS (%)
Bearish Trend 6 days ago
77%
Bearish Trend 1 day ago
44%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
61%
Bearish Trend 1 day ago
53%
Aroon
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
61%
View a ticker or compare two or three
Interact to see
Advertisement
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MAEGX15.180.22
+1.47%
BlackRock Unconstrained Equity Instl
RNWEX88.100.20
+0.23%
American Funds New World R4
FDESX36.71N/A
N/A
Fidelity Advisor Diversified Stock O
LMUSX24.94N/A
N/A
Franklin U.S. Large Cap Equity FI
EVDAX20.90N/A
N/A
Camelot Event Driven A

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with IMNM. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then IMNM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
-4.04%
IMNM - IDYA
60%
Loosely correlated
-0.11%
CGON - IDYA
60%
Loosely correlated
-0.46%
NRIX - IDYA
58%
Loosely correlated
+0.26%
SYRE - IDYA
56%
Loosely correlated
-4.99%
CRNX - IDYA
56%
Loosely correlated
-1.22%
More